Innovative GFAP blood biomarker test expands Labcorp's (LH) portfolio of tests for diseases including Alzheimer's disease, multiple sclerosis, glioblastoma and brain injuries BURLINGTON, N.C., April ...
BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp, a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta Amyloid ...
Seniors experiencing memory problems and cognitive decline now have access to a new diagnostic blood test to detect Alzheimer’s disease. Labcorp this week unveiled the first Food and Drug ...
BURLINGTON, N.C., Oct. 23, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys pTau181 test, the ...
BURLINGTON – Global life science giant Labcorp is rolling out a test that it says can speed up a diagnosis for Alzheimer’s and thus lead to earlier intervention to fight the deadly disease. The test ...
Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive ...
Labcorp Holdings, Inc. LH has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback